These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
491 related articles for article (PubMed ID: 17329087)
1. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Dahan A; Hoffman A Eur J Pharm Biopharm; 2007 Aug; 67(1):96-105. PubMed ID: 17329087 [TBL] [Abstract][Full Text] [Related]
2. Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation. Han SF; Yao TT; Zhang XX; Gan L; Zhu C; Yu HZ; Gan Y Int J Pharm; 2009 Sep; 379(1):18-24. PubMed ID: 19508887 [TBL] [Abstract][Full Text] [Related]
3. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Dahan A; Hoffman A Pharm Res; 2006 Sep; 23(9):2165-74. PubMed ID: 16902814 [TBL] [Abstract][Full Text] [Related]
4. Fast-dissolving microparticles fail to show improved oral bioavailability. Wong SM; Kellaway IW; Murdan S J Pharm Pharmacol; 2006 Oct; 58(10):1319-26. PubMed ID: 17034654 [TBL] [Abstract][Full Text] [Related]
5. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. Dahan A; Hoffman A J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294 [TBL] [Abstract][Full Text] [Related]
6. In vitro-in vivo correlations of self-emulsifying drug delivery systems combining the dynamic lipolysis model and neuro-fuzzy networks. Fatouros DG; Nielsen FS; Douroumis D; Hadjileontiadis LJ; Mullertz A Eur J Pharm Biopharm; 2008 Aug; 69(3):887-98. PubMed ID: 18367386 [TBL] [Abstract][Full Text] [Related]
8. Bioavailability of seocalcitol III. Administration of lipid-based formulations to minipigs in the fasted and fed state. Grove M; Müllertz A; Pedersen GP; Nielsen JL Eur J Pharm Sci; 2007 May; 31(1):8-15. PubMed ID: 17383165 [TBL] [Abstract][Full Text] [Related]
9. Correlation of in vitro and in vivo models for the oral absorption of peptide drugs. Föger F; Kopf A; Loretz B; Albrecht K; Bernkop-Schnürch A Amino Acids; 2008 Jun; 35(1):233-41. PubMed ID: 17726639 [TBL] [Abstract][Full Text] [Related]
10. The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. Dahan A; Duvdevani R; Shapiro I; Elmann A; Finkelstein E; Hoffman A J Control Release; 2008 Feb; 126(1):1-9. PubMed ID: 18082281 [TBL] [Abstract][Full Text] [Related]
11. Bioavailability of seocalcitol II: development and characterisation of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides. Grove M; Müllertz A; Nielsen JL; Pedersen GP Eur J Pharm Sci; 2006 Jun; 28(3):233-42. PubMed ID: 16650738 [TBL] [Abstract][Full Text] [Related]
12. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug. Fujioka Y; Metsugi Y; Ogawara K; Higaki K; Kimura T Int J Pharm; 2008 Mar; 352(1-2):36-43. PubMed ID: 18037251 [TBL] [Abstract][Full Text] [Related]
14. Prediction of oral absorption of griseofulvin, a BCS class II drug, based on GITA model: utilization of a more suitable medium for in-vitro dissolution study. Fujioka Y; Kadono K; Fujie Y; Metsugi Y; Ogawara K; Higaki K; Kimura T J Control Release; 2007 Jun; 119(2):222-8. PubMed ID: 17442444 [TBL] [Abstract][Full Text] [Related]
15. Development of an in vitro/in vivo correlation for lipid formulations of EMD 50733, a poorly soluble, lipophilic drug substance. Schamp K; Schreder SA; Dressman J Eur J Pharm Biopharm; 2006 Apr; 62(3):227-34. PubMed ID: 16246538 [TBL] [Abstract][Full Text] [Related]
16. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach. Fei Y; Kostewicz ES; Sheu MT; Dressman JB Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116 [TBL] [Abstract][Full Text] [Related]
17. Effect of prokinetic agents, cisapride and metoclopramide, on the bioavailability in humans and intestinal permeability in rats of ranitidine, and intestinal charcoal transit in rats. Lee HT; Lee YJ; Chung SJ; Shim CK Res Commun Mol Pathol Pharmacol; 2000; 108(5-6):311-23. PubMed ID: 11958284 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. Wong SM; Kellaway IW; Murdan S Int J Pharm; 2006 Jul; 317(1):61-8. PubMed ID: 16647232 [TBL] [Abstract][Full Text] [Related]
19. Examination of the impact of a range of Pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone. Sek L; Boyd BJ; Charman WN; Porter CJ J Pharm Pharmacol; 2006 Jun; 58(6):809-20. PubMed ID: 16734982 [TBL] [Abstract][Full Text] [Related]
20. Enhancement of bioavailability of griseofulvin by its complexation with beta-cyclodextrin. Dhanaraju MD; Kumaran KS; Baskaran T; Moorthy MS Drug Dev Ind Pharm; 1998 Jun; 24(6):583-7. PubMed ID: 9876628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]